Study guide
1.2 How to Navigate and Master This Study Guide
CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide
2 Chapter 2: Cancer & Cancer Treatment Modalities
2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging
3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors
4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome
5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination
5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes
6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety
6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology
7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics
7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics
1.2 How to Navigate and Master This Study Guide
Key Takeaways Explain This Topic AI
Study guide chapters strictly map to the four CDR CSO domains, integrating clinical decision-making, validated assessment tools, and evidence-based medical nutrition therapy (MNT).
The Patient-Generated Subjective Global Assessment (PG-SGA) serves as the primary oncology nutrition screening and assessment tool, with scores >=9 indicating a critical need for urgent symptom management.
Malnutrition diagnosis requires applying GLIM criteria (combining >=1 Phenotypic and >=1 Etiologic criteria), while cancer cachexia is staged using Fearon consensus definitions (Precachexia, Cachexia, Refractory Cachexia).
High-yield therapeutic topics include Pancreatic Enzyme Replacement Therapy (PERT) meal dosing, GI acute Graft-versus-Host Disease (GVHD) nutritional staging, and herb-drug interactions such as St. John's Wort inducing CYP3A4.
Effective board preparation requires active recall, vignette synthesis, understanding diagnostic cutoffs, and mastering clinical management algorithms.
Last updated: August 2026
1.2 How to Navigate and Master This Study Guide
Quick Summary: Success on the CDR CSO examination requires mastering validated clinical screening tools, diagnostic consensus definitions, metabolic frameworks, and evidence-based interventions. This study guide is structured to parallel the official CDR exam domains while prioritizing high-yield clinical topics including PG-SGA scoring, GLIM malnutrition criteria, Fearon cachexia staging, ESPEN oncology guidelines, PERT dosing, GVHD nutritional management, and herb-drug interactions.
Study Guide Architecture and Clinical Focus
This study guide is engineered specifically for Registered Dietitians preparing for the CDR Specialist in Oncology Nutrition Examination. Rather than presenting generic clinical nutrition concepts, every chapter, section, table, diagram, and practice quiz covers the topics of the official CDR CSO content specification outline.
How the Guide Covers the Exam Domains
The study guide prioritizes clinical scenario application over simple memorization. Board exam items frequently present detailed patient vignettes—such as a patient with head and neck cancer undergoing concurrent chemoradiation presenting with severe mucositis and odynophagia, a post-Whipple pancreatic adenocarcinoma patient experiencing severe malabsorption and steatorrhea, or a stem cell transplant patient developing acute GI GVHD—requiring candidates to synthesize assessment data, select appropriate diagnostic criteria, and prescribe precise nutritional interventions.
Strategic Practice Quiz and Active Recall Methodology
To maximize knowledge retention and exam readiness, candidates should utilize an active recall strategy when completing the embedded section quizzes:
Simulate Exam Conditions: Analyze every clinical vignette thoroughly without immediately viewing answer choices. Formulate an independent diagnostic or intervention hypothesis first.
Understand Rationale Mechanics: Focus on why a specific clinical option is standard-of-care while other options are inappropriate, insufficient, or contraindicated. The exam tests nuanced clinical decision-making.
Target High-Yield Clinical Algorithms: Re-visit content blocks for any missed questions, specifically focusing on diagnostic cutoffs, medication dosing protocols, and validated screening scores.
Core High-Yield Diagnostic Frameworks & Clinical Tools
Mastering the CSO examination requires deep familiarity with six landmark clinical frameworks and assessment systems. These topics appear repeatedly across multiple exam domains.
1. Patient-Generated Subjective Global Assessment (PG-SGA)
The PG-SGA is recognized internationally as the gold standard for nutritional assessment in oncology. It consists of two distinct sections:
Patient-Completed Section (Box 1-4): Evaluates weight history, food intake changes, nutrition-impact symptoms (nausea, mucositis, dysgeusia, early satiety, xerostomia, pain), and functional status.
Clinician-Completed Section: Evaluates disease status and metabolic demand, metabolic stress levels, and physical assessment (loss of subcutaneous fat, muscle wasting at temples/clavicles/quadriceps, ankle/sacral edema, ascites).
PG-SGA Numerical Score Triaged Action & Clinical Intervention Strategy
0 – 1 No nutrition intervention required at present. Reassess at routine clinical intervals.
2 – 3 Patient and family education by dietitian or trained nurse clinician.
4 – 8 Requires intervention by a dietitian in conjunction with physician/nurse care team.
≥ 9 Indicates critical need for urgent symptom management and individual nutrition triage/intervention.
2. GLIM Criteria for Malnutrition Diagnosis
The Global Leadership Initiative on Malnutrition (GLIM) framework provides a standardized 2-step model for diagnosing malnutrition in adults across clinical settings:
Step 1: First-line Screening: Identify risk using a validated screening tool (e.g., PG-SGA, MUST, NRS-2002).
Step 2: Diagnostic Confirmation: Requires at least 1 Phenotypic Criterion AND at least 1 Etiologic Criterion .
Criterion Type Parameter Categories Specific Clinical Thresholds
Phenotypic Criteria Non-volitional Weight Loss >5% within past 6 months, or >10% beyond 6 months.
Low Body Mass Index (BMI) <20 kg/m² if <70 years old; <22 kg/m² if ≥70 years old.
Reduced Muscle Mass Confirmed by DEXA, BIA, CT scan (L3 skeletal muscle index), or reduced calf/arm muscle circumference.
Etiologic Criteria Reduced Food Intake / Assimilation ≤50% of energy requirements for >1 week, or any reduction for >2 weeks, or chronic GI conditions impairing absorption.
Disease Burden / Inflammation Acute disease/trauma or chronic disease-related systemic inflammation (elevated C-reactive protein).
3. Fearon International Consensus Staging for Cancer Cachexia
Cancer cachexia is a multi-factorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support. The Fearon Consensus Framework stages cachexia into three distinct clinical phases:
Precachexia: Involuntary weight loss ≤5% accompanied by early clinical or metabolic signs (e.g., impaired glucose tolerance, systemic inflammation).
Cancer Cachexia: Diagnosed when a patient meets ANY of the following clinical thresholds:
- Involuntary weight loss >5% over the past 6 months (in the absence of simple starvation); OR
- BMI <20 kg/m² combined with ongoing involuntary weight loss >2% ; OR
Sarcopenia (reduced muscle mass) combined with ongoing involuntary weight loss >2% .
Refractory Cachexia: Advanced, catabolic state driven by tumor progression; non-responsive to oncology treatments; severe muscle wasting; functional performance score low (ECOG 3-4); life expectancy <3 months . Nutritional support shifts entirely to palliative comfort and symptom mitigation.
4. ESPEN Guidelines for Nutrition in Cancer
The European Society for Clinical Nutrition and Metabolism (ESPEN) provides foundational evidence-based guidelines for oncology nutrition management:
Total Energy Expenditure: Recommended base energy target is 25 to 30 kcal/kg/day .
Protein Requirement: Recommended protein intake is 1.0 to 1.5 g/kg/day , expanding up to 2.0 g/kg/day in severely catabolic, hypermetabolic oncology patients.
Physical Activity: Combining nutritional support with resistance exercise to maintain skeletal muscle mass and metabolic function.
Enteral/Parenteral Indications: Enteral nutrition (EN) is indicated when oral intake remains <50% of requirements for >7 days. Parenteral nutrition (PN) is reserved for severe enteritis, short bowel syndrome, severe radiation mucositis, or complete mechanical bowel obstruction.
High-Yield Pharmacology, Therapeutics, and Supplement Safety
Candidates must master targeted pharmaceutical and nutritional therapeutics frequently encountered on the CSO exam.
Pancreatic Enzyme Replacement Therapy (PERT)
Indicated for pancreatic exocrine insufficiency (PEI) following pancreaticoduodenectomy (Whipple procedure), total pancreatectomy, or pancreatic head adenocarcinoma:
Initial Dosing: 500 lipase units/kg/meal (or 25,000 to 50,000 USP lipase units per main meal; 10,000 to 25,000 units per snack).
Administration Timing: Must be taken with the first bites of meals/snacks . Capsules must not be mixed with hot liquids or crushed (enteric-coated microspheres must remain intact to survive gastric acid).
Graft-versus-Host Disease (GVHD) Nutritional Staging
Gastrointestinal acute GVHD post-allogeneic hematopoietic stem cell transplant (HSCT) presents with severe watery diarrhea, abdominal cramping, mucosal desquamation, and GI bleeding:
Phase I (Gut Rest): NPO status with total parenteral nutrition (TPN) during severe secretory diarrhea (>1,000 mL/day).
Phase II (Reintroduction): Transition to low-residue, lactose-free, low-fat oral liquids as diarrhea decreases (<500 mL/day).
Phase III (Advance): Gradual expansion to solid, low-spiced, easily digestible foods as gut integrity recovers.
High-Risk Supplement and Drug Interactions
Natural Health Product Mechanism of Interaction Clinical Impact on Oncology Therapy
St. John's Wort Induces CYP3A4 and P-glycoprotein (P-gp) drug-metabolizing enzymes. Significantly lowers systemic blood levels of targeted therapies (e.g., imatinib, irinotecan), reducing therapeutic efficacy.
High-Dose Antioxidants (Vit C, Vit E) Scavenges reactive oxygen species (ROS). May attenuate the pro-oxidative mechanism of radiation therapy and alkylating chemotherapy agents.
Green Tea Extract (EGCG) Directly binds the boronic acid structure of bortezomib. Completely blocks the therapeutic action of bortezomib in multiple myeloma.